Is bioMmune Technologies Inc’s Fuel Running Low? The Stock Just Gapped Down

 Is bioMmune Technologies Inc's Fuel Running Low? The Stock Just Gapped Down

The stock of bioMmune Technologies Inc (CVE:IMU) gapped down by $0.02 today and has $0.40 target or 4.00% below today’s $0.42 share price. The 7 months technical chart setup indicates high risk for the $14.50 million company. The gap down was reported on Nov, 28 by If the $0.40 price target is reached, the company will be worth $580,000 less.
Gaps down are helpful for identifying a resistance level and to could also be used as a tradeable event. If traders are short the stock and it experiece gap down, then its usually advisable to hold the short for a bigger down move. Back-tests of such patterns show that two-thirds of the these patterns the stock performance worsens after the gap. The area gaps close 91% of the time, the breakaway gaps 1%, the continuation gaps 9% and the exhaustion gaps 64%. About 25,000 shares traded hands or 36.02% up from the average. bioMmune Technologies Inc (CVE:IMU) has risen 6.00% since October 29, 2016 and is uptrending. It has underperformed by 0.01% the S&P500.

More notable recent bioMmune Technologies Inc (CVE:IMU) news were published by: which released: “bioMmune Technologies Inc. Announces Appointment of Directors” on December 09, 2015, also with their article: “BioMmune Technologies Inc. Announces the Appointment of Dr. Karoly Nikolich to …” published on September 24, 2013, published: “BioMmune Appoints Thomas Gadek, PhD, to Board of Directors” on September 20, 2016. More interesting news about bioMmune Technologies Inc (CVE:IMU) were released by: and their article: “BioMmune, A 2016 TSX Venture Top 50 Company, Awarded Patent for Calcium …” published on June 29, 2016 as well as‘s news article titled: “Biotech Stock Directory Update” with publication date: August 14, 2014.

Biommune Technologies Inc, formerly MC Partners Inc, is a Canada biopharmaceutical company. The company has a market cap of $14.50 million. The Firm is a research and development issuer. It currently has negative earnings. The Firm is engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment